EP866 - ECE_2713 - Continuous glucose monitoring in prediabetes and newly diagnosed type 2 diabetes: a pilot case series
Year: 2026
Type: conference-abstract
Abstract: Introduction Type 2 diabetes mellitus (T2DM) and prediabetes are major global health challenges due to high prevalence, asymptomatic early stages, and risk of cardiovascular and microvascular complications. By 2050, the number of people with diabetes is projected to reach 852.5 million, with 90%-95% of cases being T2DM. Early detection and glycemic control are crucial, but conventional self-monitoring provides limited insight into daily glucose fluctuations, particularly postprandial. Continuous glucose monitoring (CGM) enables detailed assessment of glycemic variability and may support personalized early management. Aim To evaluate the clinical and metabolic utility of CGM in patients with prediabetes and newly diagnosed T2DM. Materials and Methods This pilot observational case series included two patients: a 26-year-old woman with prediabetes, obesity class I, and subclinical hypothyroidism, and a 61-year-old man with newly diagnosed T2DM, obesity class I, and hypertension. Both underwent CGM for one month. CGM data were analyzed alongside anthropometrics, body composition, lipid profile, markers of carbohydrate metabolism (fasting plasma glucose, HbA1c, fructosamine, C-peptide, HOMA-2), and health-related quality of life (SF-36). Patients received standard pharmacological therapy and lifestyle guidance tailored using CGM findings. Results In the prediabetes patient, baseline HbA1c was 5.7% with normal fasting glucose (4.9 mmol/L). CGM revealed postprandial hyperglycemic excursions not detected by routine labs. After one month, body weight decreased from 88.5 to 85.8 kg, body fat from 46.7% to 43.7%, and visceral fat from 12 to 11. Fructosamine decreased from 225.6 to 218.7 µmol/L, HDL cholesterol increased from 0.95 to 1.1 mmol/L, and quality-of-life scores improved, particularly physical functioning (80→90) and vitality (60→80). In the T2DM patient, baseline HbA1c was 6.73% and fasting glucose 7.27 mmol/L. After one month, fasting glucose decreased to 6.77 mmol/L. Weight remained stable (89.5 kg), but waist circumference decreased from 103 to 100.5 cm, body fat from 33.5% to 31.5%, visceral fat from 20 to 17, and lean mass increased from 59.5 to 61.3 kg. Triglycerides decreased from 1.5 to 1.1 mmol/L, HDL cholesterol increased from 1.1 to 1.3 mmol/L, and emotional well-being improved from 64 to 84. Conclusions CGM provides clinically relevant insights into glycemic variability in prediabetes and newly diagnosed T2DM, including postprandial excursions undetected by conventional labs. Even over a short period, CGM-guided management improved glycemic control, body composition, lipid profile, and quality of life. Follow-up assessments at 3 and 12 months will evaluate the durability of metabolic effects, patient motivation, and long-term prevention of disease progression.
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,292
OpenAlex ID: W7213266341